New drug cocktail aims to stop rare liver cancer from coming back
NCT ID NCT07243951
First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tests whether combining an immunotherapy drug (cadonilimab) with a chemotherapy pill (capecitabine) can prevent a rare mixed liver cancer from returning after surgery. About 75 adults who had their tumor completely removed but are at medium-to-high risk of recurrence will receive the combo for up to 6 months. Researchers will measure how long patients stay cancer-free and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.